Home
Be Kind to your Kidneys
Careers
Transition
Revised Pipeline Animated Graphic
Editable Therapeutic Areas
Senior Leadership
Chris Cline
Peter Heerma
Eric Dube, Ph.D.
Laura M. Clague, CPA
Noah L. Rosenberg, M.D.
Jula Inrig, M.D.
Laura M. Johnson
Casey Logan
William Rote, Ph.D.
Elizabeth Reed, J.D.
Medical Education Grants
About Us
COVID-19
Our Culture
Equity, Diversity & Inclusion
Our Why
Privacy
Individual Rights Request Form
Thank you
California Privacy Policy
Clinical Trials Privacy Policy
Website Cookies Policy
Corporate Privacy Policy
Patient Advocacy
Diagnostic Testing Programs
INVESTIGATOR-SPONSORED RESEARCH
Contact Us
Thank You for Contacting Us
Our Pipeline
TVT-058
ALGS COLLABORATION
Sparsentan for IgAN
Sparsentan for FSGS
Chenodeoxycholic Acid (CDCA) Program
NGLY1 Collaboration
Clinical Trials
Our Therapies
Board of Directors
Suzanne L. Bruhn, Ph.D.
Sandra E. Poole
Gary A. Lyons
Ruth Williams-Brinkley
Roy D. Baynes, M.D., Ph.D.
Tim Coughlin, CPA
Jeffrey A. Meckler
John A. Orwin
Ron Squarer
Pathfinder
Expanded Access
Terms & Conditions
Community Guidelines
Patients & Caregivers
Therapeutic Areas
Classical Homocystinuria (HCU)
ALAGILLE SYNDROME (ALGS)
IgA NEPHROPATHY (IgAN)
N-GLYCANASE 1 (NGLY1) DEFICIENCY
FOCAL SEGMENTAL GLOMERULOSCLEROSIS (FSGS)
CYSTINURIA
CEREBROTENDINOUS XANTHOMATOSIS (CTX)
PEROXISOME BIOGENESIS DISORDER-ZELLWEGER SPECTRUM DISORDER (PBD-ZSD)
BILE ACID SYNTHESIS DISORDERS (BASD)
Search
Menu
Menu
You are here:
Home
1
/
Transition
Retrophin is now
Travere Therapeutics.
Read More
×
Scroll to top